Project overview Joint Funding
Afatinib (Afatinib in NRG1-rearranged KRAS wild-type malignancies)
Program: MTT Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: pancreatic cancer Status: completed
AMI2GO (Amplify Immunological Insights by Glioma Organoids)
Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Frankfurt/Mainz, Heidelberg Entity: brain tumor Status: current
AMPLIFY-NEOVAC (Amplifying Neoepitope-specific Vaccine Responses in progressive diffuse gliomas)
Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Heidelberg, Munich, Tubingen Entity: brain tumor Status: current
ARMANI (Resection of liver mets in patients with RAS-mutated CoCa)
Program: MDEB Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: colon cancer Status: current
CAR2BRAIN (Immune response CAR-NK immunotherapy in glioblastoma)
Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Dresden, Frankfurt/Mainz, Heidelberg Entity: brain tumor Status: completed
CD276xCD3 (FIH study evaluating CR276xCD3 bsAb CC-3 in CRC)
Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: colon cancer Status: current
CHOICE (Osteo-hematopoietic niche & malignant evolution)
Program: EOM Funding Line: INNOVATION Project type: research project Partner site: Dresden, Frankfurt/Mainz, Munich Entity: blood cancer Status: completed
Decode-UM (Decoding the cellular ecosystem of uveal melanoma for monitoring and therapeutic targeting)
Program: CI Funding Line: INNOVATION Project type: research project Partner site: Berlin, Essen/Dusseldorf, Heidelberg, Tubingen Entity: skin cancer Status: current
DKTK Surgery (Individualized surgical oncology of gastrointestinal tumors)
Programs: Overarching Funding Line: strategic initiative Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: colon cancer, pancreatic cancer Status: completed
EPIC-G8 (GeparOcto-methylation profiling)
Program: MDEB Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Heidelberg, Munich Entity: breast cancer Status: completed
Evaluation of New Therapeutic Concepts in Relapsed AML
Program: MTT Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Frankfurt/Mainz, Freiburg, Munich Entity: blood cancer Status: completed
EXLIQUID (ExploitLiquid)
Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: current
Ga-PSMA-11 in high-risk prostate cancer
Program: ROI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Dresden, Essen/Dusseldorf, Freiburg, Heidelberg, Munich, Tubingen Entity: prostate cancer Status: completed
HematoTrac (Hematopoietic trajectories in cancer)
Program: EOM Funding Line: INNOVATION Project type: research project Partner site: Essen/Dusseldorf, Frankfurt/Mainz, Freiburg Entity: brain tumor Status: current
HYPERBOLIC (Hyperpolarized MRI of Cancer Metabolism & Markers)
Program: ROI Funding Line: INNOVATION Project type: research project Partner site: Freiburg, Heidelberg, Munich, Tubingen Entity: brain tumor, breast cancer Status: current
IDENTI-T (Precision monitoring and targeting of T-ALL)
Program: MDEB Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Frankfurt/Mainz, Heidelberg Entity: blood cancer Status: current
IMMUNED (Predictive Biomarker for Adjuvant Immunotherapy)
Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Essen/Dusseldorf, Heidelberg, Tubingen Entity: skin cancer Status: current
ImmuNeoMASTER (Impact of mutational pathways on immune environment, neoantigens and tumor rejection for the development of comprehensive biomarker panels and combinatorial approaches in cancer immunotherapy)
Program: CI Funding Line: INNOVATION Project type: research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: completed
INFORM (Individualized Therapy for Relapsed Malignancies in Childhood)
Program: MDEB Funding Line: INNOVATION Project type: research project Partner site: Berlin, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: cancer in childhood and adolescence, multiple entities Status: completed
INFORM/MASTER PRO
Program: MTT Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: completed
INVENT4GB (Intraventricular TCR therapy for glioblastoma)
Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Frankfurt/Mainz, Heidelberg, Tubingen Entity: brain tumor Status: current
IVAC-AN (Neoantigen Recognition by Vaccine-induced T-Cells)
Program: CI Funding Line: UPGRADE Project type: study-related research project Partner site: Berlin, Essen/Dusseldorf, Munich, Tubingen Entity: blood cancer Status: current
iVacALL (Prospective phase I/II study: Patient-individualized peptide vaccination based on whole exome sequencing with adjuvant GM-CSF and IFNa in children with relapsed acute lymphoblastic leukemia)
Program: CI Funding Line: INNOVATION Project type: IIT/clinical study Partner site: Berlin, Essen/Dusseldorf, Heidelberg, Munich, Tubingen Entity: blood cancer Status: completed
JF-PSMA (Combined molecular and imaging-based characterization and prognostication of primary high risk prostate cancer from the multicenter 68Ga-PSMA-11 DKTK trial)
Program: ROI Funding Line: UPGRADE Project type: study-related research project Partner site: Dresden, Essen/Dusseldorf, Freiburg, Heidelberg, Munich Entity: prostate cancer Status: current
JIP (DKTK Joint Imaging Platform)
Programs: Overarching Funding Line: strategic initiative Project type: technology platform Partner site: Berlin, Dresden, Essen/Dusseldorf, Frankfurt/Mainz, Freiburg, Heidelberg, Munich, Tubingen Entity: multiple entities Status: current